BioCardia, Inc.
NASDAQ: BCDAW0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Peter A. Altman
- Employees
- 16
- Headquarters
- Sunnyvale, United States
- IPO year
- 2019
- Market cap
- $10.1K
- Website
- https://www.biocardia.com
Loading BCDAW…
Loading profile data…Frequently asked questions about BCDAW
What does BioCardia, Inc. (BCDAW) do?
BioCardia, Inc. is a regenerative medicine enterprise, currently in the clinical development phase, dedicated to devising cell-based and cell-derived treatments for cardiac and pulmonary ailments. Its primary therapeutic offering is CardiAMP, an autologous mononuclear cell therapy system designed to address heart failure and persistent myocardia...
Where does BCDAW trade?
BioCardia, Inc. (BCDAW) trades on the NASDAQ Capital Market.
What sector is BCDAW in?
BioCardia, Inc. (BCDAW) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of BioCardia, Inc.?
Peter A. Altman is the chief executive officer of BioCardia, Inc. (BCDAW).
Where is BioCardia, Inc. headquartered?
BioCardia, Inc. is headquartered in United States.
Does BCDAW pay a dividend?
BioCardia, Inc. (BCDAW) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did BCDAW go public?
BioCardia, Inc. (BCDAW) completed its initial public offering in 2019.